Cargando…

Opportunities for improving the efficiency of paediatric HIV treatment programmes

OBJECTIVES: To conduct two economic analyses addressing whether to: routinely monitor HIV-infected children on antiretroviral therapy (ART) clinically or with laboratory tests; continue or stop cotrimoxazole prophylaxis when children become stabilized on ART. DESIGN AND METHODS: The ARROW randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Revill, Paul A., Walker, Simon, Mabugu, Travor, Nathoo, Kusum J., Mugyenyi, Peter, Kekitinwa, Adeodata, Munderi, Paula, Bwakura-Dangarembizi, Mutsawashe, Musiime, Victor, Bakeera-Kitaka, Sabrina, Nahirya-Ntege, Patricia, Walker, A. Sarah, Sculpher, Mark J., Gibb, Diana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318642/
https://www.ncbi.nlm.nih.gov/pubmed/25396263
http://dx.doi.org/10.1097/QAD.0000000000000518
_version_ 1782355870242308096
author Revill, Paul A.
Walker, Simon
Mabugu, Travor
Nathoo, Kusum J.
Mugyenyi, Peter
Kekitinwa, Adeodata
Munderi, Paula
Bwakura-Dangarembizi, Mutsawashe
Musiime, Victor
Bakeera-Kitaka, Sabrina
Nahirya-Ntege, Patricia
Walker, A. Sarah
Sculpher, Mark J.
Gibb, Diana M.
author_facet Revill, Paul A.
Walker, Simon
Mabugu, Travor
Nathoo, Kusum J.
Mugyenyi, Peter
Kekitinwa, Adeodata
Munderi, Paula
Bwakura-Dangarembizi, Mutsawashe
Musiime, Victor
Bakeera-Kitaka, Sabrina
Nahirya-Ntege, Patricia
Walker, A. Sarah
Sculpher, Mark J.
Gibb, Diana M.
author_sort Revill, Paul A.
collection PubMed
description OBJECTIVES: To conduct two economic analyses addressing whether to: routinely monitor HIV-infected children on antiretroviral therapy (ART) clinically or with laboratory tests; continue or stop cotrimoxazole prophylaxis when children become stabilized on ART. DESIGN AND METHODS: The ARROW randomized trial investigated alternative strategies to deliver paediatric ART and cotrimoxazole prophylaxis in 1206 Ugandan/Zimbabwean children. Incremental cost-effectiveness and value of implementation analyses were undertaken. Scenario analyses investigated whether laboratory monitoring (CD4(+) tests for efficacy monitoring; haematology/biochemistry for toxicity) could be tailored and targeted to be delivered cost-effectively. Cotrimoxazole use was examined in malaria-endemic and non-endemic settings. RESULTS: Using all trial data, clinical monitoring delivered similar health outcomes to routine laboratory monitoring, but at a reduced cost, so was cost-effective. Continuing cotrimoxazole improved health outcomes at reduced costs. Restricting routine CD4(+) monitoring to after 52 weeks following ART initiation and removing toxicity testing was associated with an incremental cost-effectiveness ratio of $6084 per quality-adjusted life-year (QALY) across all age groups, but was much lower for older children (12+ years at initiation; incremental cost-effectiveness ratio = $769/QALY). Committing resources to improve cotrimoxazole implementation appears cost-effective. A healthcare system that could pay $600/QALY should be willing to spend up to $12.0 per patient-year to ensure continued provision of cotrimoxazole. CONCLUSION: Clinically driven monitoring of ART is cost-effective in most circumstances. Routine laboratory monitoring is generally not cost-effective at current prices, except possibly CD4(+) testing amongst adolescents initiating ART. Committing resources to ensure continued provision of cotrimoxazole in health facilities is more likely to represent an efficient use of resources.
format Online
Article
Text
id pubmed-4318642
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-43186422015-02-17 Opportunities for improving the efficiency of paediatric HIV treatment programmes Revill, Paul A. Walker, Simon Mabugu, Travor Nathoo, Kusum J. Mugyenyi, Peter Kekitinwa, Adeodata Munderi, Paula Bwakura-Dangarembizi, Mutsawashe Musiime, Victor Bakeera-Kitaka, Sabrina Nahirya-Ntege, Patricia Walker, A. Sarah Sculpher, Mark J. Gibb, Diana M. AIDS Epidemiology and Social OBJECTIVES: To conduct two economic analyses addressing whether to: routinely monitor HIV-infected children on antiretroviral therapy (ART) clinically or with laboratory tests; continue or stop cotrimoxazole prophylaxis when children become stabilized on ART. DESIGN AND METHODS: The ARROW randomized trial investigated alternative strategies to deliver paediatric ART and cotrimoxazole prophylaxis in 1206 Ugandan/Zimbabwean children. Incremental cost-effectiveness and value of implementation analyses were undertaken. Scenario analyses investigated whether laboratory monitoring (CD4(+) tests for efficacy monitoring; haematology/biochemistry for toxicity) could be tailored and targeted to be delivered cost-effectively. Cotrimoxazole use was examined in malaria-endemic and non-endemic settings. RESULTS: Using all trial data, clinical monitoring delivered similar health outcomes to routine laboratory monitoring, but at a reduced cost, so was cost-effective. Continuing cotrimoxazole improved health outcomes at reduced costs. Restricting routine CD4(+) monitoring to after 52 weeks following ART initiation and removing toxicity testing was associated with an incremental cost-effectiveness ratio of $6084 per quality-adjusted life-year (QALY) across all age groups, but was much lower for older children (12+ years at initiation; incremental cost-effectiveness ratio = $769/QALY). Committing resources to improve cotrimoxazole implementation appears cost-effective. A healthcare system that could pay $600/QALY should be willing to spend up to $12.0 per patient-year to ensure continued provision of cotrimoxazole. CONCLUSION: Clinically driven monitoring of ART is cost-effective in most circumstances. Routine laboratory monitoring is generally not cost-effective at current prices, except possibly CD4(+) testing amongst adolescents initiating ART. Committing resources to ensure continued provision of cotrimoxazole in health facilities is more likely to represent an efficient use of resources. Lippincott Williams & Wilkins 2015-01-14 2015-01-07 /pmc/articles/PMC4318642/ /pubmed/25396263 http://dx.doi.org/10.1097/QAD.0000000000000518 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights revserved. http://creativecommons.org/licenses/by-nc-nd/3.0./ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0.
spellingShingle Epidemiology and Social
Revill, Paul A.
Walker, Simon
Mabugu, Travor
Nathoo, Kusum J.
Mugyenyi, Peter
Kekitinwa, Adeodata
Munderi, Paula
Bwakura-Dangarembizi, Mutsawashe
Musiime, Victor
Bakeera-Kitaka, Sabrina
Nahirya-Ntege, Patricia
Walker, A. Sarah
Sculpher, Mark J.
Gibb, Diana M.
Opportunities for improving the efficiency of paediatric HIV treatment programmes
title Opportunities for improving the efficiency of paediatric HIV treatment programmes
title_full Opportunities for improving the efficiency of paediatric HIV treatment programmes
title_fullStr Opportunities for improving the efficiency of paediatric HIV treatment programmes
title_full_unstemmed Opportunities for improving the efficiency of paediatric HIV treatment programmes
title_short Opportunities for improving the efficiency of paediatric HIV treatment programmes
title_sort opportunities for improving the efficiency of paediatric hiv treatment programmes
topic Epidemiology and Social
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318642/
https://www.ncbi.nlm.nih.gov/pubmed/25396263
http://dx.doi.org/10.1097/QAD.0000000000000518
work_keys_str_mv AT revillpaula opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes
AT walkersimon opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes
AT mabugutravor opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes
AT nathookusumj opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes
AT mugyenyipeter opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes
AT kekitinwaadeodata opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes
AT munderipaula opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes
AT bwakuradangarembizimutsawashe opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes
AT musiimevictor opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes
AT bakeerakitakasabrina opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes
AT nahiryantegepatricia opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes
AT walkerasarah opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes
AT sculphermarkj opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes
AT gibbdianam opportunitiesforimprovingtheefficiencyofpaediatrichivtreatmentprogrammes